Table 3.
Cox proportional hazards models of predictors of survival based on platinum free interval.
| 3–6 months | 7–12 months | >12 months | |
|---|---|---|---|
| HR (95%CI) | HR (95%CI) | HR (95%CI) | |
| Age | |||
| 65–69 | Referent | Referent | Referent |
| 70–74 | 1.03 (0.83, 1.29) | 0.99 (0.80, 1.22) | 1.25 (1.05, 1.50)* |
| 75–79 | 1.29 (1.01, 1.66)* | 1.22 (0.97, 1.52) | 1.56 (1.28, 1.89)** |
| ≥80 | 1.08 (0.78, 1.49) | 1.14 (0.87, 1.49) | 1.75 (1.37, 2.24)** |
| Race/ethnicity | |||
| White | Referent | Referent | Referent |
| Black | 0.93 (0.61, 1.43) | 0.98 (0.67, 1.43) | 0.87 (0.58, 1.32) |
| Other/Unknown | 0.90 (0.57, 1.43) | 0.72 (0.49, 1.06) | 0.89 (0.61, 1.31) |
| Marital status | |||
| Married | Referent | Referent | Referent |
| Unmarried | 1.07 (0.88, 1.30) | 0.94 (0.80, 1.11) | 1.11 (0.96, 1.27) |
| Other | 0.99 (0.51, 1.94) | 1.10 (0.72, 1.69) | 0.84 (0.47, 1.49) |
| Residence | |||
| Non-metropolitan | Referent | Referent | Referent |
| Metropolitan | 1.15 (0.81, 1.62) | 1.07 (0.80, 1.43) | 0.83 (0.64, 1.07) |
| Socioeconomic status | |||
| Lowest (first) quintile | Referent | Referent | Referent |
| Second quintile | 1.19 (0.88, 1.60) | 0.92 (0.71, 1.19) | 0.86 (0.69, 1.08) |
| Third quintile | 1.05 (0.76, 1.46) | 1.04 (0.79, 1.36) | 0.99 (0.77, 1.27) |
| Fourth quintile | 1.11 (0.83, 1.48) | 0.91 (0.70, 1.18) | 0.93 (0.73, 1.19) |
| Highest (fifth) quintile | 0.91 (0.67, 1.23) | 0.90 (0.69, 1.19) | 0.88 (0.68, 1.12) |
| Registry area | |||
| Eastern | Referent | Referent | Referent |
| Midwest | 1.22 (0.94, 1.60) | 1.11 (0.90, 1.38) | 1.03 (0.84, 1.27) |
| West | 1.08 (0.83, 1.39) | 0.99 (0.80, 1.24) | 1.03 (0.85, 1.25) |
| Diagnosis year | |||
| 1993–1998 | Referent | Referent | Referent |
| 1999–2004 | 1.35 (0.99, 1.84) | 1.20 (0.91, 1.60) | 0.92 (0.76, 1.11) |
| 2005–2009 | 1.24 (0.90, 1.72) | 1.19 (0.88, 1.60) | 0.83 (0.66, 1.05) |
| Comorbidity Score | |||
| 0 | Referent | Referent | Referent |
| 1 | 1.00 (0.80, 1.25) | 0.96 (0.78, 1.17) | 1.06 (0.89, 1.25) |
| ≥2 | 1.29 (0.94, 1.76) | 1.16 (0.89, 1.51) | 1.33 (1.04, 1.71)* |
| Histology | |||
| Serous | Referent | Referent | Referent |
| Mucinous | 5.08 (2.50, 10.32)** | 0.94 (0.46, 1.90) | 1.41 (0.85, 2.34) |
| Endometrioid | 0.71 (0.46, 1.11) | 1.20 (0.86, 1.68) | 0.79 (0.60, 1.04) |
| Clear Cell | 0.78 (0.41, 1.50) | 1.62 (0.87, 3.03) | 1.31 (0.81, 2.11) |
| Other | 1.09 (0.82, 1.43) | 1.08 (0.86, 1.37) | 1.07 (0.88, 1.31) |
| Stage | |||
| I | Referent | Referent | Referent |
| II | 1.86 (0.67, 5.14) | 0.51 (0.26, 0.99)* | 0.82 (0.56, 1.20) |
| III | 1.89 (0.75, 4.73) | 0.89 (0.52, 1.53) | 0.99 (0.73, 1.34) |
| IV | 2.17 (0.86, 5.46) | 1.11 (0.64, 1.92) | 1.07 (0.77, 1.49) |
| Unknown | 3.31 (1.14, 9.56)* | 1.00 (0.50, 1.97) | 1.09 (0.67, 1.75) |
| Grade | |||
| 1 | Referent | Referent | Referent |
| 2 | 1.03 (0.45, 2.33) | 0.86 (0.48, 1.54) | 0.85 (0.54, 1.34) |
| 3 | 0.95 (0.43, 2.09) | 0.86 (0.50, 1.50) | 0.95 (0.62, 1.45) |
| Unknown | 0.93 (0.41, 2.10) | 0.84 (0.47, 1.49) | 0.90 (0.57, 1.44) |
| Neoadjuvant chemotherapy | |||
| No | Referent | Referent | Referent |
| Yes | 1.62 (1.26, 2.08)* | 1.20 (0.95, 1.51) | 0.87 (0.66, 1.14) |
| Initial chemotherapy duration (months) | |||
| 1 to 4 | Referent | Referent | Referent |
| 5 to 6 | 1.01 (0.82, 1.24) | 0.99 (0.82, 1.18) | 0.98 (0.84, 1.14) |
| 7 to 8 | 1.34 (1.02, 1.77)* | 1.07 (0.81, 1.40) | 0.93 (0.72, 1.19) |
| Recurrent chemotherapy regimen | |||
| Non-platinum | Referent | Referent | Referent |
| Platinum alone | 0.70 (0.47, 1.06) | 0.81 (0.63, 1.04) | 0.75 (0.60, 0.94)* |
| Platinum combination | 0.59 (0.48, 0.74)** | 0.75 (0.62, 0.89)* | 0.54 (0.47, 0.63)** |
*
P<0.05,
**
P<0.0001